现代结核病控制策略的实施进展及系统评价

中国防痨杂志 ›› 2012, Vol. 34 ›› Issue (9): 585-591.

现代结核病控制策略的实施进展及系统评价

成诗明刘二勇王芳马艳周林王黎霞万利亚

102206 北京，中国疾病预防控制中心结核病预防控制中心(成诗明、刘二勇、周林、王黎霞)；中国医学科学院医学信息研究所基层卫生与妇幼保健研究室（王芳）；北京市结核病胸部肿瘤研究所中心办公室（马艳）；中国防痨协会秘书处（万利亚）

收稿日期:2012-05-16 出版日期:2012-09-10 发布日期:2012-12-17
通信作者: 成诗明 E-mail:smcheng@chinatb.org
基金资助:
艾滋病和病毒性肝炎等重大传染病防治科技重大专项（2009ZX10004-216）

Systematic review and implemention progress of DOTS strategy

CHENG Shi-ming, LIU Er-yong, WANG Fang, MA Yan, ZHOU Lin, WANG Li-xia, WAN Li-ya

National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention,Beijing 102206,China

Received:2012-05-16 Online:2012-09-10 Published:2012-12-17
Contact: CHENG Shi-ming E-mail:smcheng@chinatb.org

摘要/Abstract

摘要： 目的描述及评价DOTS策略的实施情况。方法由邀请的专家和文献检索人员讨论后确定检索的文献内容和检索词，共检索12个数据库、4个卫生机构网站和搜索引擎Google Scholar，纳入1999—2010年所有描述或评价已经实施的DOTS策略、成本-效益分析、防控经验等的文章记录共2182条，并对文章信息进行提取。结果共纳入26篇文章及WHO年报,其中WHO年报11篇，评价DOTS策略实施的文章10篇,对DOTS策略实施进行成本-效益分析文章5篇。通过实施DOTS策略患者治愈率提高了13.1%～92.1%不等、治疗成功率提高到了92.4%～95.0%不等、登记率增加了163.0%～217.8%不等；降低了患病率30.0%～50.0%及丢失率73.0%～52.6%不等，同时实施DOTS策略提高了成本-效益。结论强有力的政府承诺是保持DOTS策略可持续实施的前提，DOTS策略的实施有效地控制了结核病的疫情，同时具有良好的成本-效益。

关键词: 结核/预防和控制, 卫生计划实施, 费用效益分析, 评价研究

Abstract: Objective To describe and review the implementation progress of DOTS strategy. Methods Through discussion with the invited experts, we determined the key words of retrival literature, and searched 12 database, 4 health agencies websites and Google Scholar. A total of 2182 papers between 1990—2010 were searched out including papers describing or evaluating DOTS strategy, cost-effectiveness analysis, experience on prevention and control. Results Of the 26 studies included in the analysis, 11 studies were WHO annual reports, 10 studies aimed to describe and evaluate DOTS strategy, 5 studies aimed to evaluate the effectiveness of DOTS strategy; the implementation of the DOTS strategy raised the cure rates by 13.1%-92.1%,the treatment success rate increased to 92.4%-95.0%, the registration rate increased by 163.0%-217.8%; prevalence rate and the loss rate decreased by 30.0%-50.0% and 73.0%-52.6% respectively. In addition, implementation of the DOTS strategy improved the cost-effectiveness as well. Conclusion The strong government commitment is prerequisite for sustainable implementation of the strategy, effective implementation of the DOTS strategy put the TB under control, meanwhile has a good cost-effectiveness.

Key words: Tuberculosis/prevention &, control, Health plan implementation, Cost-benefit analysis, Evaluation studies

成诗明刘二勇王芳马艳周林王黎霞万利亚. 现代结核病控制策略的实施进展及系统评价[J]. 中国防痨杂志, 2012, 34(9): 585-591.

CHENG Shi-ming, LIU Er-yong, WANG Fang, MA Yan, ZHOU Lin, WANG Li-xia, WAN Li-ya. Systematic review and implemention progress of DOTS strategy[J]. Chinese Journal of Antituberculosis, 2012, 34(9): 585-591.

参考文献

［1］WHO. Global tuberculosis control report 2010. Geneva: World Health Organization, 2010.

［2］WHO. Global tuberculosis control: a short update to the 2009 report. Geneva:World Health Organization, 2009.

［3］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2008.Geneva: World Health Organization, 2008.

［4］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2007.Geneva: World Health Organization, 2007.

［5］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2006.Geneva: World Health Organization, 2006.

［6］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2005.Geneva: World Health Organization, 2005.

［7］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2004.Geneva: World Health Organization, 2004.

［8］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2003.Geneva: World Health Organization, 2003.

［9］WHO. Global tuberculosis control: Surveillance, Planning, Financing: WHO report 2002.Geneva: World Health Organization, 2002.

［10］WHO. Global tuberculosis control: WHO report 2001.Geneva: World Health Organization, 2001.

［11］WHO. Global tuberculosis control: WHO report 1997. Geneva: World Health Organization, 1997.

［12］Ushio M.Amendment of tuberculosis prevention law and prospect of tuberculosis control program. Kekkaku,2005,80(7):541-546.

［13］Shimao T. Tuberculosis prevalence survey in Japan. Kekkaku,2009, 84(11):713-720.

［14］Subramani R, Santha T, Frieden TR, et al. Active community surveillance of the impact of different tuberculosis control measures, Tiruvallur, South India, 1968—2001. Int J Epidemiol,2007,36(2):387-393.

［15］Xianyi C, Fengzeng Z, Hongjin D, et al. The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ, 2002,80(6):430-436.

［16］Yassin MA, Datiko DG, Shargie EB. Ten-year experiences of the tuberculosis control programme in the southern region of Ethiopia. Int J Tuberc Lung Dis,2006,10(10):1166-1171.

［17］China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet,2004, 364(9432):417-422.

［18］Marica C, Didilescu C, Galie N, et al. Reversing the tuberculosis upwards trend: a success story in Romania. Eur Respir J,2009,33(1):168-170.

［19］Sharma S, Sarin R, Khalid UK, et al. The DOTS strategy for treatment of paediatric pulmonary tuberculosis in South Delhi,India.Int J Tuberc Lung Dis, 2008,12(1):74-80.

［20］Romero-Sandoval N, Flores-Carrera O, Molina MA, et al. DOTS strategy and community participation: an experience in the Ecuadorian Andes. Int J Tuberc Lung Dis,2009,13(12):1569-1571.

［21］Shargie EB,Lindtjorn B.DOTS improves treatment outcomes and service coverage for tuberculosis in South Ethiopia: a retrospective trend analysis. BMC Public Health, 2005,5:62.

［22］Zalesky R, Abdullajev F, Khechinashvili G, et al. Tuberculosis control in the Caucasus: successes and constraints in DOTS implementation.Int J Tuberc Lung Dis,1999,3(5):394-401.

［23］Subramani R, Radhakrishna S, Frieden TR, et al. Rapid decline in prevalence of pulmonary tuberculosis after DOTS implementation in a rural area of South India.Int J Tuberc Lung Dis,2008,12(8):916-920.

［24］Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ,2005,331(7529):1364.

［25］Pantoja A, Lonnroth K, Lal SS, et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness.Int J Tuberc Lung Dis,2009,13(6):705-712.

［26］Xu Q, Jin SG, Zhang LX. Cost effectiveness of DOTS and non-DOTS strategies for smear-positive pulmonary tuberculosis in Beijing. Biomed Environ Sci,2000,13(4):307-313.

［27］Murray CJ, DeJonghe E, Chum HJ, et al. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet,1991,338(8778):1305-1308.

［28］de Jonghe E, Murray CJ, Chum HJ,et al.Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania. Int J Health Plann Manage,1994, 9(2):151-181.

［29］Floyd K, Arora VK, Murthy KJ, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India.Bull World Health Organ, 2006,84(6):437-445.

［30］Raviglione MC,Sudre P,Rieder HL,et al.Secular trends of tuberculosis in western Europe. Bull World Health Organ,1993,71(3/4):297-306.

［31］Rieder HL, Cauthen GM, Comstock GW, et al. Epidemiology of tuberculosis in the United States. Epidemiol Rev,1989,11:79-98.

［32］McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med, 1995,332(16):1071-1076.

［33］Suárez PG, Watt CJ, Alarcón E,et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis, 2001,184(4):473-478.

［34］Frieden TR. Can tuberculosis be controlled? Int J Epidemiol, 2002,31(5):894-899.

［35］Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City—turning the tide. N Engl J Med,1995,333(4):229-233.

[1]	陈凤芳, 马俊, 黄劲, 尹洪云, 沙巍, 杨光红, 冯永红. 建立结核感染T淋巴细胞斑点试验阳性的纵隔淋巴结结核与Ⅰ/Ⅱ期结节病诊断模型初探[J]. 中国防痨杂志, 2020, 42(8): 832-837.
[2]	段李明, 丁超, 刘玉钢, 韦林, 谷振宁. 电视辅助胸腔镜手术在慢性结核性脓胸治疗中的应用价值[J]. 中国防痨杂志, 2020, 42(8): 850-853.
[3]	陈振华,刘彬彬,陈忠南,谭云洪. 病原学阴性初治肺结核患者诊断模型的建立及初步评价[J]. 中国防痨杂志, 2020, 42(3): 266-271.
[4]	刘彬彬,龚道方,陈振华,郭婧玮,余艳艳,刘丰平,欧阳辉,谭云洪. 三种实验室诊断技术对结核分枝杆菌复合群检出率及检测费用的比较研究[J]. 中国防痨杂志, 2020, 42(2): 143-148.
[5]	陈品儒,谭守勇. 外科手术在非结核分枝杆菌肺病治疗中的作用探讨[J]. 中国防痨杂志, 2020, 42(2): 159-163.
[6]	马改霞,田黎明,王钰,邱磊,薛玲娜,鹿振辉,张惠勇,郭晓燕. 中西医结合治疗耐多药肺结核的系统评价/Meta分析的再评价[J]. 中国防痨杂志, 2020, 42(2): 95-100.
[7]	辜吉秀, 李晴, 马玲, 李银花, 王冬冬, 司红艳. 高通量二代测序技术在耐药结核病诊断中的应用[J]. 中国防痨杂志, 2020, 42(11): 1203-1208.
[8]	王泽明, 孙琳, 申阿东. 儿童结核病临床实践指南的现状与思考[J]. 中国防痨杂志, 2020, 42(10): 1025-1028.
[9]	白云松, 张学军, 曹隽, 冯磊, 祁新禹, 郭东, 姚子明, 李承鑫. 一期前后路联合手术治疗儿童腰椎结核的临床疗效分析[J]. 中国防痨杂志, 2020, 42(10): 1048-1052.
[10]	毛毅, 曾义岚, 吴桂辉, 江智豪, 范琳. 肺结核患者临床特征与外周血流式细胞亚群的相关性分析[J]. 中国防痨杂志, 2020, 42(10): 1080-1086.
[11]	宁锋钢,周新华,侯代伦,吕平欣,吕岩,贺伟. 成年血行播散性肺结核并发颅内结核的临床及头颅MRI表现特征[J]. 中国防痨杂志, 2020, 42(1): 19-25.
[12]	任航空,段李明,郑琴芳. 两种技术对不同手术标本进行检测诊断胸壁结核的价值[J]. 中国防痨杂志, 2020, 42(1): 74-78.
[13]	张宏伟,许静,马煜,邓亚丽. 陕西省基本公共卫生结核病患者健康管理服务项目实施效果评价[J]. 中国防痨杂志, 2019, 41(9): 951-956.
[14]	汪娟,许缃,蔡晓峰,杨美霞. 对糖尿病患者进行肺结核筛查的效果与成本效益分析[J]. 中国防痨杂志, 2019, 41(9): 968-973.
[15]	陈曦,刘忠泉,王彬,朱慧,付雷,李媛媛,陆宇. 14种抗结核药物在巨噬细胞内的抗结核活性评价[J]. 中国防痨杂志, 2019, 41(9): 993-998.